Nasopharyngeal carcinoma: nimotuzumab linked to improved survival of patients treated with IMRT

  • Zhi-Qiang W & al.
  • BMC Cancer
  • 19 Nov 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding the monoclonal antibody nimotuzumab to intensity-modulated radiotherapy (IMRT) is associated with improved survival outcomes of patients with stage III-IVb nasopharyngeal carcinoma (NPC).

Why this matters

  • Treatment outcomes for NPC are often unfavorable, necessitating new options.

Key results

  • At a median follow-up of 74.78 months, overall mortality was 16.03%, the locoregional failure rate was 9.32%, the distant failure rate was 9.73%, and 1.34% of patients experienced locoregional failure and distant metastases.
  • Nimotuzumab+IMRT was associated with improved 5-year distant metastasis-free survival (DMFS; 93.09% vs 85.61%; P=.012) and OS (88.91% vs 78.30%; P=.006) compared with IMRT alone.
  • Nimotuzumab+IMRT and IMRT alone were associated with similar 5-year locoregional relapse-free survival (85.34% vs 89.79%; P=.156) and PFS (79.96% vs 77.99%; P=.117).
  • Nimotuzumab was independently associated with DMFS (HR, 2.317; P=.010) and OS (HR, 2.125; P=.004) in multivariate analysis.

Study design

  • 730 patients with stage III-IVb NPC, 184 treated with nimotuzumab+IMRT and 546 with IMRT alone, were analyzed for survival outcomes after propensity matching.
  • Funding: None.

Limitations

  • Retrospective study.